News from viiv healthcare A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

05 Mar, 2018, 17:00 GMT ViiV Healthcare Announces Positive New Dolutegravir Data for the Treatment of People Living With HIV Co-Infected With Tuberculosis

INSPIRING study results contribute to the extensive body of evidence for dolutegravir, the leading integrase strand transfer inhibitor, in diverse...


22 Nov, 2017, 00:35 GMT Juluca® (Dolutegravir and Rilpivirine) Approved in US as First 2-drug Regimen, Once-daily, Single Pill - a Complete Regimen for the Maintenance Treatment of Virologically Suppressed HIV-1 Infection

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today...


25 Jul, 2017, 14:03 BST ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings

DAWNING study modified to allow patients the opportunity to receive dolutegravir-based regimens ViiV Healthcare, the global specialist HIV company,...


16 Aug, 2016, 13:55 BST ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment

ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®)...


18 Jul, 2016, 11:15 BST ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV

ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy...


10 Jun, 2016, 14:15 BST ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV

Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that ...


24 Feb, 2016, 17:12 GMT ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented...


23 Feb, 2016, 19:49 GMT ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment

32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen ViiV...


07 Jan, 2016, 13:31 GMT ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration with...


03 Nov, 2015, 13:24 GMT ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Phase IIb study ...


26 Oct, 2015, 14:27 GMT ViiV Healthcare Awards 23 Small Grants to Help Alleviate the Stigma of HIV and AIDS in the MSM and Transgender Community Globally

ViiV Healthcare today awarded its first round of small grants to support men who have sex with men (MSM) and transgender community-led interventions...


23 Sep, 2015, 10:27 BST New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq® Maintains HIV Viral Suppression

ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study, an open-label study evaluating the efficacy, safety and...


02 Jul, 2015, 08:00 BST ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries

Agreement reinforces ViiV Healthcare commitment to improving access to HIV treatments ViiV Healthcare and Desano Pharmaceuticals (Desano) today...


26 May, 2015, 14:00 BST ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV

ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an...


06 May, 2015, 09:51 BST ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine ViiV Healthcare today announced the start of a Phase III...


04 Dec, 2014, 16:39 GMT Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug...


27 Nov, 2014, 14:06 GMT ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV

The Positive Action for Children Fund (PACF) is proud to announce 103 grants for 2015 totalling £5 million. 54 new grants and 49 extensions will be...


03 Sep, 2014, 15:05 BST ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV

ViiV Healthcare announced today that the European Commission (EC) has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir...


22 Aug, 2014, 21:01 BST ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and...


27 Jun, 2014, 14:32 BST Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV

ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a...


12 Jun, 2014, 11:44 BST ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland Ltd (Janssen) for the development and...


03 Feb, 2014, 12:00 GMT New HIV Treatment Launched by ViiV Healthcare Addresses Multiple Evolving Needs of People Living With HIV in the UK

ViiV Healthcare today launches its first new treatment, the integrase inhibitor, dolutegravir (TIVICAY®) a treatment for human immunodeficiency virus ...


21 Jan, 2014, 12:09 GMT ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

ViiV Healthcare today announced that the European Commission has approved Tivicay™ (dolutegravir), an integrase inhibitor, for use in combination...


22 Nov, 2013, 14:00 GMT Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV

ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a...


25 Oct, 2013, 13:23 BST ViiV Healthcare announces European regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV

ViiV Healthcare today announced the submission of a regulatory application in Europe for its investigational single-tablet regimen (STR) combining...